Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate

SpringerPlus

Volumn 2, Issue 1, 2013, Pages 1-10

  Dessì, Mariele ^a   Madeddu, Clelia ^a   Piras, Alessandra ^a   Cadeddu, Christian ^a   Antoni, Giorgia ^a   Mercuro, Giuseppe ^a   Mantovani, Giovanni ^a,b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b Policlinico Universitario   (Italy)

Author keywords

Cytokines; Epirubicin induced cardiotoxicity; Oxidative stress; RAS; Telmisartan

Indexed keywords

EID: 84878792862     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-2-198     Document Type: Article

References (33)

1. Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160(3):e481-e487, 487.
2. Cardinale D, Colombo A, Cipolla CM (2008) Prevention and treatment of cardiomyopathy and heart failure in patients receiving cancer chemotherapy. Curr Treat Options Cardiovasc Med 10(6):486-495.
3. Cardinale D, Bacchiani G, Beggiato M, Colombo A, Cipolla CM (2013) Strategies to prevent and treat cardiovascular risk in cancer patients. Semin Oncol 40(2):186-198.
4. Cianchetti S, Del Fiorentino A, Colognato R, Di Stefano R, Franzoni F, Pedrinelli R (2008) Anti-inflammatory and anti-oxidant properties of telmisartan in cultured human umbilical vein endothelial cells. Atherosclerosis 198(1):22-28.
5. Colombo A, Cardinale D (2013) Using cardiac biomarkers and treating cardiotoxicity in cancer. Future Cardiol 9(1):105-118.
6. Conklin KA (2005) Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 4(2):110-130.
7. Dessi M, Piras A, Madeddu C, Cadeddu C, Deidda M, Massa E, Antoni G, Mantovani G, Mercuro G (2011) Long-term protective effects of the angiotensin receptor blocker Telmisartan on Epirubucin-induced inflammation, oxidative stress and myocardial dysfunction. Exper Therapeutic Med 2:1003-1009.
8. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J (2004) Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2(4):385-399.
9. Ferreira AL, Matsubara LS, Matsubara BB (2008) Anthracycline-induced cardiotoxicity. Cardiovasc Hematol Agents Med Chem 6(4):278-281.
10. Funao K, Matsuyama M, Kawahito Y, Sano H, Chargui J, Touraine JL, Nakatani T, Yoshimura R (2008) Telmisartan is a potent target for prevention and treatment in human prostate cancer. Oncol Rep 20(2):295-300.
11. Iqbal M, Dubey K, Anwer T, Ashish A, Pillai KK (2008) Protective effects of telmisartan against acute doxorubicin-induced cardiotoxicity in rats. Pharmacol Rep 60(3):382-390.
12. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H (2007) Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 67(9):924-932.
13. Jalowy A, Schulz R, Heusch G (1998) AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res Cardiol 93(Suppl 2):85-91.
14. Jensen BV, Skovsgaard T, Nielsen SL (2002) Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncol 13(5):699-709.
15. Jones S, Holmes FA, O'Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H, Savin MA (2009) Docetaxel with Cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and Cyclophosphamide: 7-year follow- Up of US oncology research trial 9735. J Clin Oncol 27(8):1177-1183.
16. Kaur K, Sharma AK, Dhingra S, Singal PK (2006) Interplay of TNF-alpha and IL-10 in regulating oxidative stress in isolated adult cardiac myocytes. J Mol Cell Cardiol 41(6):1023-1030.
17. Khasraw M, Bell R, Dang C (2012) Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast 21(2):142-149.
18. Kupatt C, Habazettl H, Goedecke A, Wolf DA, Zahler S, Boekstegers P, Kelly RA, Becker BF (1999) Tumor necrosis factor-alpha contributes to ischemia- and reperfusion-induced endothelial activation in isolated hearts. Circ Res 84 (4):392-400.
19. Mantovani G, Madeddu C, Cadeddu C, Dessi M, Piras A, Massa E, Serpe R, Antoni G, Mercuro G (2008) Persistence, up to 18 months of follow-up, of epirubicininduced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 13(12):1296-1305.
20. Meldrum DR, Cleveland JC Jr, Cain BS, Meng X, Harken AH (1998) Increased myocardial tumor necrosis factor-alpha in a crystalloid-perfused model of cardiac ischemia-reperfusion injury. Ann Thorac Surg 65(2):439-443.
21. Mercuro G, Cadeddu C, Piras A, Dessi M, Madeddu C, Deidda M, Serpe R, Massa E, Mantovani G (2007) Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Oncologist 12(9):1124-1133.
22. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56(2):185-229.
23. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649-655.
24. Paulides M, Wojnowski L (2007) Chemotherapeutics-induced heart failure. Med Klin (Munich) 102(7):574-578.
25. Pelliccia F, Pasceri V, Cianfrocca C, Vitale C, Speciale G, Gaudio C, Rosano GM, Mercuro G (2010) Angiotensin II receptor antagonism with telmisartan increases number of endothelial progenitor cells in normotensive patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Atherosclerosis 210(2):510-515.
26. Sipahi I, Debanne SM, Rowland DY, Simon DI, Fang JC (2010) Angiotensinreceptor blockade and risk of cancer: meta-analysis of randomised controlled trials. Lancet Oncol 11(7):627-636.
27. Soga M, Kamal FA, Watanabe K, Ma M, Palaniyandi S, Prakash P, Veeraveedu P, Mito S, Kunisaki M, Tachikawa H, Kodama M, Aizawa Y (2006) Effects of angiotensin II receptor blocker (candesartan) in daunorubicin-induced cardiomyopathic rats. Int J Cardiol 110(3):378-385.
28. Stephen RL, Gustafsson MC, Jarvis M, Tatoud R, Marshall BR, Knight D, Ehrenborg E, Harris AL, Wolf CR, Palmer CN (2004) Activation of peroxisome proliferatoractivated receptor delta stimulates the proliferation of human breast and prostate cancer cell lines. Cancer Res 64(9):3162-3170.
29. Thompson KL, Rosenzweig BA, Zhang J, Knapton AD, Honchel R, Lipshultz SE, Retief J, Sistare FD, Herman EH (2010) Early alterations in heart gene expression profiles associated with doxorubicin cardiotoxicity in rats. Cancer Chemother Pharmacol 66(2):303-314.
30. Toko H, Oka T, Zou Y, Sakamoto M, Mizukami M, Sano M, Yamamoto R, Sugaya T, Komuro I (2002) Angiotensin II type 1a receptor mediates doxorubicininduced cardiomyopathy. Hypertens Res 25(4):597-603.
31. Tuck ML (2005) Angiotensin-receptor blocking agents and the peroxisome proliferator-activated receptor-gamma system. Curr Hypertens Rep 7(4):240-243.
32. Wenzel P, Schulz E, Oelze M, Muller J, Schuhmacher S, Alhamdani MS, Debrezion J, Hortmann M, Reifenberg K, Fleming I, Munzel T, Daiber A (2008) AT1- receptor blockade by telmisartan upregulates GTP-cyclohydrolase I and protects eNOS in diabetic rats. Free Radic Biol Med 45(5):619-626.
33. Yamagishi S, Takeuchi M (2005) Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property. Med Hypotheses 64(3):476-478